Cart
sales@molnova.com
Ziyuglycoside II
CAS No. 35286-59-0
Ziyuglycoside II( —— )
Catalog No. M18467 CAS No. 35286-59-0
Ziyuglycoside II has anticancer, and antitumor properties against gastric cancer and breast cancer cells, by cell cycle arrest and cell apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 106 | In Stock |
|
| 10MG | 157 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameZiyuglycoside II
-
NoteResearch use only, not for human use.
-
Brief DescriptionZiyuglycoside II has anticancer, and antitumor properties against gastric cancer and breast cancer cells, by cell cycle arrest and cell apoptosis.
-
DescriptionZiyuglycoside II has anti-inflammation and antioxidation properties. Ziyuglycoside II has antibiosis, and homeostasis properties. Ziyuglycoside II has anticancer, and antitumor properties against gastric cancer and breast cancer cells, by cell cycle arrest and cell apoptosis.
-
In VitroCell Viability Assay Cell Line:MDA-MB-435 cells Concentration:10, 20, 30, 40, 50, 60 μM Incubation Time:24 hours and 48 hours Result:The IC50 at 24 h and 48 h was 5.92 μM and 4.74 μM, respectively. Cell Cycle Analysis Cell Line:MDA-MB-435 cells Concentration:5, 10, 25 μM Incubation Time:24 hours Result:Induced G0/G1 and S phase arrest. Apoptosis Analysis Cell Line:MDA-MB-435 cells Concentration:5, 10, 25 μM Incubation Time:24 hours Result:The apoptotic rate was significantly increased in comparison to that of the control.Western Blot Analysis Cell Line:MDA-MB-435 cells Concentration:5, 10, 25 μM Incubation Time:24 hours Result:Treatment resulted in increased expressions of both p53 and p21.
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGluR
-
RecptorAntioxidant
-
Research AreaCancer|Inflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number35286-59-0
-
Formula Weight604.82
-
Molecular FormulaC35H56O8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (82.67 mM)
-
SMILESCC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC6C(C(C(CO6)O)O)O)C)C)C2C1(C)O)C)C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PD168393
PD168393 is an irreversible EGFR inhibitor (IC50: 0.70 nM), irreversibly alkylate Cys-773; inactive against PKC, FGFR, PDGFR, and insulin.
-
Valiglurax
Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species.
-
Basimglurant
Basimglurant is a potent, selective and orally available modulator of mGlu5 negative allosteric(Kd of 1.1 nM). In competition binding experiments on human recombinant mGlu5, Basimglurant (RG7090) fully displaces [3H]-MPEP with a Ki of 35.6 nM and [3H]-ABP688 with a Ki of 1.4 nM. In HEK293 cells stably expressing human mGlu5, Basimglurant (RG7090) inhibits quisqualate induced Ca2+ mobilization with an IC50 of 7.0 nM and [3H]-inositolphosphate accumulation (IC50 of 5.9 nM).
